论文部分内容阅读
[目的]评价食管瘤同步放化疗的疗效。[方法]回顾性分析1983年1月至1992年12月353例无锁骨上转移的食管癌。按治疗方法分三级：Ⅰ组：单纯放疗301例，放疗剂量48Gy－75Gy；Ⅱ组：放疗加平阳霉素26例，放疗剂量50Gy－76Gy，平阳霉素10mg肌注，每周1－2次，共6－7周；Ⅲ组：放疗加顺钻26例，放疗剂量54Gy－70Gy，顺钢20mg－30mg，静脉滴注，每周1－2次，共6－7周。所有病例均随访5年以上。[结果]1年生存车Ⅰ、Ⅱ、Ⅲ组分别为48．2％、61．5％和53．8％，三组间无统计学差异。3年生存率各组分别为21．6％、26．9％和42．3％，其中Ⅲ组与Ⅰ、Ⅱ组有显著性差异（P＜0．05）。5年生存率各组分别为11．3％、154％和26．9％，Ⅲ组与Ⅰ、Ⅱ组间有显著性差异（P＜0。05）。[结论]同步放化疗可提高食管癌的疗效，尤以放疗加顺铂为佳。
[Objective] To evaluate the efficacy of concurrent radiotherapy and chemotherapy for esophageal carcinoma. [Methods] Retrospective analysis of 353 cases of esophageal cancer without supraclavicular metastasis from January 1983 to December 1992. According to the treatment method, it was divided into three levels: Group I: 301 cases of radiotherapy alone, radiation dose 48Gy-75Gy; Group II: 26 cases of radiation plus pingyangmycin, radiotherapy dose 50Gy-76Gy, Pingyangmycin 10mg intramuscular injection, 1-2 per week Second, a total of 6-7 weeks; Group III: 26 cases of radiotherapy plus cisplatin, radiotherapy dose 54Gy-70Gy, Shungang 20mg-30mg, intravenous drip, 1-2 times per week, a total of 6-7 weeks. All cases were followed up for more than 5 years. [Results] One year survival car I, II, III groups were 48.2%, 61.5% and 53.8%, respectively, there was no statistical difference between the three groups. The 3-year survival rate was 21.6%, 26.9%, and 42.3% in each group, among which there was a significant difference between group III and group I and II (P<0.05). The 5-year survival rate was 11.3%, 154%, and 26.9% in each group, and there was a significant difference between group III and group I and II (P0.05). [Conclusion] Simultaneous radiotherapy and chemotherapy can improve the efficacy of esophageal cancer, especially radiotherapy plus cisplatin.